Novel PI3K inhibitors (idelalisib, buparlisib, duvelisib and copanlisib) have recently demonstrated promise for the treatment of MALT [30–32], PCNSL [33], NKTCL [34] and PTCL [27, 34, 35]. This evidence concerns the gene PIK3CD and primary central nervous system lymphoma.